r It is unknown whether excessive reactive oxygen species (ROS) production drives the isocapnic hyperoxia (IH)-induced decline in human cerebral blood flow (CBF) via reduced nitric oxide (NO) bioavailability and leads to disruption of the blood-brain barrier (BBB) or neural-parenchymal damage.
Introduction
Inhaling oxygen-rich gas mixtures is a standard therapy for a range of clinical conditions (Farquhar et al. 2009; Puccio et al. 2009 ). Nevertheless, supplemental oxygen has also been related to brain hypoperfusion (Kety & Schmidt, 1948; Floyd et al. 2003) , convulsive activity (Turrens, 2003) , neuronal-parenchymal injury (Kuisma et al. 2006) and increased mortality risk (Rawles & Kenmure, 1976; Wijesinghe et al. 2009; Kilgannon et al. 2011) . Brain hypoperfusion may be a consequence of paradoxical hyperventilation and the resulting decrease in the arterial pressure of carbon dioxide (P aCO 2 ) (Watson et al. 2000; Dean et al. 2004) . Hypocapnia would then drive a preferential decrease in perfusion of the anterior cerebral circulation as the posterior network of the brain vessels demonstrates reduced reactivity to changes in P aCO 2 (Sato et al. 2012) . While hypocapnia explains the reduction in human brain perfusion during poikilocapnic hyperoxaemia, a controversial isocapnic hyperoxia (IH)-evoked reduction in local and total cerebral blood flow (CBF) has also been reported (Kolbitsch et al. 2002; Floyd et al. 2003; Xu et al. 2012; Ainslie et al. 2014) . Contrast-enhanced magnetic resonance imaging detected a decline of perfusion in all cerebral regions except the parietal and left hemispheric frontal grey matter (Kolbitsch et al. 2002) , suggesting a disparity in regional responses to IH. Similarly, others have stated there is an independent cerebral vasoconstrictive impact of increased arterial partial pressure of oxygen (Floyd et al. 2003) . Nonetheless, MRI and Doppler ultrasound-based evidence advocates that hyperoxia-induced decline in CBF depends on hyperventilation-evoked hypocapnia (Xu et al. 2012; Ainslie et al. 2014) and highlights the need for further investigation into the characteristics of regional and total CBF responses to IH and their unknown underlying mechanism(s).
In response to a high arterial oxygen partial pressure, IH-induced cerebral hypoperfusion is followed by a reduction in brain oxygen delivery (Brugniaux et al. 2018) . In addition, hyperoxia also inhibits the activity of the pyruvate dehydrogenase, a critical enzyme for oxidative metabolism (Bogaert et al. 1994) . These counterregulatory responses could provoke a hypothetical compensatory shift from oxidative to non-oxidative brain metabolism. Nonetheless, the impact of IH on brain metabolism is still controversial as evidence has reported either a reduction (Xu et al. 2012) or no effect (Kety & Schmidt, 1948; Ainslie et al. 2014) on the cerebral metabolic rate of oxygen (CMR O 2 ).
As a main regulator of cerebrovascular tone and CBF, nitric oxide (NO) bioavailability emerges as a potential candidate to explain IH-induced cerebral hypoperfusion (Toda et al. 2009 ). Hyperoxia leads to mitochondrial dysfunction (Turrens, 2003; Hals et al. 2017) , NADPH oxidase activation (Vignais, 2002) , as well as an excessive formation of reactive oxygen species (ROS) and reduced NO bioavailability (Beckman & Koppenol, 1996) . In rats, hyperbaric oxygen exposure reduced CBF and brain NO end-products via excessive ROS production (Demchenko et al. 2002; Zhilyaev et al. 2003) , which was abolished in the presence of an increased antioxidant defence (Vucinovic et al. 2015) .
Disturbances in redox homeostasis also provoke plasma membrane oxidation (Halliwell & Gutteridge, 2015; Lagranha et al. 2017) , blood-brain barrier (BBB) disruption (Pun et al. 2009 ) and neural-parenchymal damage (Terraneo et al. 2017) . However, in a translational perspective, it is unknown whether excessive ROS production drives the reduction in the human brain blood flow via reduced NO bioavailability and leads to neural-parenchymal damage as no study has simultaneously quantified human CBF and transcerebral exchanges of NO end-products, oxidant, antioxidant and neural-parenchymal damage markers under IH. Therefore, the aim of this study was to determine whether IH affects human CBF and metabolic regulation through exaggerated reactive oxygen species (ROS) production, reduced nitric oxide (NO) bioavailability and disturbances in the blood-brain barrier (BBB) and neural parenchymal homeostasis. We hypothesized that IH would reduce anterior and posterior blood flow, leading to a decline in total CBF and a shift from oxidative to non-oxidative brain metabolism driven by an exaggerated ROS production and a decrease in NO bioavailability with BBB disruption and neural-parenchymal damage.
Methods

Ethical approval
Before engaging in the present study, participants signed a written consent after receiving a detailed explanation of the experimental procedures. The procedures were conducted in accordance with the Declaration of Helsinki, except for registration in a database, and approved by the Ethical Committee for Research of the Fluminense Federal University (CAAE: 57077316.1.0000.5243).
Subjects
After a screening for simultaneous insonation of the left internal carotid artery (ICA) and the right vertebral artery (VA) via Doppler ultrasonography (Logiq P5, GE Healthcare, Milwaukee, WI, USA), 10 healthy, recreationally active men (24 ± 3 years; body mass index of 24 ± 2 kg m −2 ) were included in the study. Inclusion criteria also comprised: (1) no history of smoking, (2) no cardiovascular, metabolic or neurological diseases, and (3) no current pharmacological therapy or nutritional supplementation.
Instrumentation
The subjects initially rested in a supine head-down tilt (the Trendelenburg) position (−15°). An arterial catheter (1.1 mm internal diameter, 20 gauge) was inserted in the left radial artery and a venous catheter was placed into a left antecubital vein. Under local anaesthesia (2% lidocaine) and guided by a B-mode ultrasound probe, a catheter (1.6 mm internal diameter, 14 gauge; ES-04706, Arrow International, Reading, PA, USA) was inserted in the right internal jugular vein and directed to its bulb (Overgaard et al. 2012) . Subjects then underwent instrumentation to register cardiac, respiratory, haemodynamic and metabolic parameters. Non-invasive, beat-to-beat, mean arterial pressure (MAP) was recorded continuously via finger photoplethysmography (Finometer Pro; Finapres Medical Systems, Arnhem, The Netherlands) and validated by measurements of right brachial artery pressure (EM-759-E, Omron, Kyoto, Japan). Heart rate (HR) was recorded using a 3-lead electrocardiogram (BioAmp, MLA2540; ADInstruments, Bella Vista, NSW, Australia) and cardiac output (CO) was derived from the arterial pressure waveform using the Modelflow method. Breathing frequency and amplitude were registered through a piezoelectric respiratory belt transducer (MLT 1132, AdInstruments) positioned in the upper or lower abdomen. Ventilation (V E ), tidal volume, end-tidal carbon dioxide partial pressure (P ETCO 2 ), oxygen partial pressure (P O 2 ) and inspired oxygen fractions (F IO 2 ) were continuously recorded using a breath-by-breath system while the subjects breathed through a face mask connected to a gas analyser system (Ultima CPX; Medgraphics, St Paul, MN, USA), which was previously calibrated with a flow sensor. This procedure was conducted via rapid injections of air using a 3 L syringe and subsequently with a special gas mixture containing known fractions of O 2 (16%) and CO 2 (5%). Simultaneous recordings of the arterial diameter and blood velocity (BV) in the right VA and left ICA were obtained using two high-resolution Doppler ultrasound systems (Logiq E and Logiq P5, GE Healthcare) with multifrequency linear-array probes (8-12 Hz) and insonation angle-corrected (60°) blood velocity spectra. ICA measurements were taken at least 1.5 cm from the carotid bifurcation to avoid retrograde or turbulent flow. VA was insonated between C4 and C5. The sample volume was positioned in the centre of the vessels and adjusted according to their upper and lower edges. The probe locations were marked on the skin to maintain their position throughout the protocol.
Experimental design
The subjects attended a morning session at least 48 h after screening/familiarization and were instructed to avoid caffeine, alcohol, intense exercise and a high-nitrate/nitrite diet for 24 h before the experimental visit. Upon arrival at the facility, the subjects were instrumented and then rested supine in a dark, quiet and temperature-controlled (21-23°C) room. Respiratory rate,V E , tidal volume, J Physiol 597.3 F IO 2 , P ETO 2 and P ETCO 2 were monitored for 10 min while the subjects breathed normoxic gas (21% O 2 and 79% N 2 ). A normoxic 10 min average P ETCO 2 was then calculated and defined as the target for the normoxic and hyperoxic trials. An intravenous saline infusion via the left antecubital vein (500 mL, NaCl 0.9%, Fresenius Kabi, Bad Homburg vor der Höhe, Germany) was initiated and maintained at a rate of 25 mL min −1 (InfusoMat Compact, BBraun, Melsungen, Germany) until the end of the protocol. A 5 min normoxic trial (NX) began after 5 min of the saline infusion. Subsequently, subjects underwent a 10 min IH trial (100% O 2 ). Guided by a metronome, subjects breathed at a rate of 20 cycles min −1 throughout both NX and IH trials in order to prevent poikilocapnic hyperoxia-induced hyperventilation. In addition to the verbal instructions to control breathing amplitude, a rebreathing circuit was used to clamp P ETCO 2 and maintain isocapnia even in the face of sudden changes in tidal volume (Fernandes et al. 2016) . The ICA and VA diameters and BV waveform were simultaneously registered during the last 30 s of each trial. Immediately after the ultrasonography recording, arterial and jugular venous blood samples were taken simultaneously to quantify the brain metabolic profile, NO end-products (plasma nitrite), oxidant (8-isoprostane and thiobarbituric acid-reactive substances (TBARS)), antioxidant (ascorbic acid (AA) and AA plus dehydroascorbic acid (AA+DA)) and neuronal-parenchymal injury markers (neuron-specific enolase). Arterial and jugular venous blood pH, P CO 2 , P O 2 , oxygen saturation (S O 2 ), haematocrit (Hct) and haemoglobin (Hb) were immediately quantified via a blood gas analyser system (Stat Phox Plus L, Nova Biomedical, Waltham, MA, USA). The quantification of the conduit artery diameter and BV waveform and the arterial and jugular venous blood sampling were only conducted if P ETO 2 and P ETCO 2 levels indicated both isocapnic normoxic and hyperoxic breathing patterns during the NX and IH trials, respectively.
The subjects were then allowed to rest for 30 min before undergoing both isocapnic normoxic and hyperoxic trials again, with an infusion of 3 g of AA (Weigert et al. 2009 ) (200 mg mL −1 , Verbena, São Paulo, SP, Brazil) diluted in 500 mL of saline. This concentration of AA has been effectively applied to prevent ROS formation in human plasma (Frei et al. 1989) . Figure 1 shows the experimental protocol.
Ascorbic acid and ascorbic acid plus dehydroascorbic acid
Ascorbic acid (AA) and ascorbic acid plus dehydroascorbic acid (AA+DA) were assayed using high-performance liquid chromatography (HPLC) (Robitaille & Hoffer, 2015) . Four millilitres of arterial and jugular venous blood samples were simultaneously drawn and collected in K 2 EDTA-containing tubes before centrifugation at 3000 g (at 4°C) for 10 min. The plasma (0.2 mL) was added to an equal volume of 10% metaphosphoric acid in 2 mmol L −1 Na 2 EDTA, left on ice for 5 min, and then centrifuged at 16,000 g (4°C) for 10 min. The sample was stored at −20°C until the HPLC analysis. For AA, a 50 μL sample was mixed with 50 μL of 5 mmol L −1 Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) in water (pH 2) and allowed to react for 20 min in the dark at room temperature. An equal volume of water was then added. Both samples were centrifuged at 16,000 g (4°C) for 10 min and the supernatants were immediately injected onto the HPLC. The HPLC system was equipped with a Bio-Rad Fermentation Monitoring Column (150 × 7.8 mm, ID; Bio-Rad Laboratories, Hercules, CA, USA) guarded by a Bio-Rad Micro-Guard Cation H Cartridge (30 × 4.6 mm, ID), and a diode array detector (Prominence model SPD-M20A, Shimadzu, Kyoto, Japan) that monitored absorbance at 245 nm. The flow rate was 0.8 mL min
and the mobile phase consisted of 5 mM sulfuric acid.
Plasma nitrite
Arterial and internal jugular venous blood plasma nitrite levels were determined via the chemiluminescence reaction of NO with ozone conducted by an NO analyser (Sievers, Boulder, CO, USA) (Garcia et al. 2016) . Briefly, blood was sampled into trace metal-free tubes containing sodium heparin. After deproteinization with cold ethanol, the supernatant was injected into a purge vessel containing iodide and acetic acid at room temperature, which converted nitrite to NO (Metzger et al. 2006) . The plasma nitrite concentration was determined by interpolation of a nitrite standard curve (Nagababu & Rifkind, 2010) .
Oxidative stress and neuronal-parenchymal damage
Lipid peroxidation starts with the reaction of a free radical with polyunsaturated fatty acids resulting in malondialdehyde (MDA) formation. MDA reacts with thiobarbituric acid (TBA) and generates a coloured product (Asakawa & Matsushita, 1980) . Human plasma (100 μL) was homogenized with 50 μL of sodium dodecyl sulphate (SDS; 8.1%), 550 μL of phosphoric acid (H 3 PO 4 , 1%) and 300 μL of TBA (0.6%). After 1 h incubation at 95°C, the solution was centrifuged for 5 min at 4000 rpm. The supernatant was used to quantify the TBARS concentration in a 96-well microplate reader (Synergy H1, Biotech, Winooski, VT, USA). The assay absorbance was determined at 532 nm. Plasma 8-isoprostane and neuron-specific enolase (NSE) were analysed by a competitive enzyme-linked immunosorbent assay (ELISA) using commercial kits (STAT-8-isoprostane, Cayman, MI, and Human enolase 2 Immunoassay Quantikine R ELISA kit, R&D Systems, Minneapolis, MN, USA, respectively) according to the manufacturer's instructions. The 8-isoprostane concentration and NSE levels were determined via interpolation from a standard curve and samples were analysed in duplicate. The assay absorbances in the microplate reader were determined at 420 and 540 nm, respectively.
Data analysis and calculations
Ventilatory and Doppler ultrasound parameters were manually synchronized, while other signals were registered at a 1 kHz sampling rate using an analog-to-digital data acquisition system (PowerLab, software LabChart 7 for Mac OS; ADInstruments). The data were then stored for off-line analysis. BV was obtained from the intensity-weighted mean frequency (TAMean) (Blanco, 2015) over all cardiac cycles that occurred during the last 30 s of each NX and IH trial. TAMean is the time-averaged velocity of the Doppler spectrum occurring along a specific or an integral number of cardiac cycles (Blanco, 2015) . For arterial diameters, B-mode video signals were encoded in real time, captured by a USB video board (Easycap, DC60; Leadership, São Paulo, SP, Brazil), and stored as digital AVI files. The files were transferred to edge detection and wall-tracking software (Vascular Analyzer for Research, version: 5.10.8, Medical Imaging Applications, Coralville, IA, USA) . Regions of interest within the optimal portions of the images were identified and did not change during the analysis. Vessel diameters were determined without application of an R-wave gating function. Blood flow (BF), vascular conductance (VC) and CO fractional distribution (COF) were calculated from both the NX and IH trials as follows:
Total cerebral blood flow (tCBF), volumetric total conductance (VTVC), molar tCBF (mtCBF) per unit of cerebral tissue and molar VTVC (mVTVC) were derived from ICA and VABF as follows:
Arterial oxygen content (C aO 2 (mL dL −1 )) was estimated as ([Hb] × 1.36 × (S aO 2 (%))/100 + 0.003 × P aO 2 ), where [Hb] represents the haemoglobin concentration in arterial blood (g dL −1 ), 1.36 is the amount of O 2 (mL) carried by 1 g of haemoglobin at 100% S aO 2 , S aO 2 is the arterial oxygen saturation, 0.003 is the amount of oxygen (mL dL −1 ) dissolved in blood, and P aO 2 is the partial pressure of oxygen.
ICA oxygen delivery (ICA D O 2 ), VA oxygen delivery (VA D O 2 ) and total cerebral oxygen delivery (CD O 2 ) were calculated as follows:
CMR O 2 , cerebral delivery of glucose (CD Glu ) and cerebral delivery of lactate (CD Lac ) and their metabolic rates (CMR Glu and CMR Lac , respectively) were also determined as follows:
Where AGlu is arterial glucose, ALac is arterial lactate, VGlu is venous glucose and VLac is venous lactate. Brain oxygen extraction fraction (EF O 2 ), glucose extraction fraction (EF Glu ), and lactate extraction fraction (EF Lac ) were also determined as follows:
Oxygen glucose (OGI) and carbohydrate (OCI) indices were obtained as follows: 87.7 ± 4.4 88.1 ± 7.6 88.3 ± 4.9 91.8 ± 7.5 CO (L min −1 ) 6 . 6 ± 2.4 6.5 ± 2.5 6.8 ± 2.3 6.7 ± 2.0 P ETO 2 (mmHg) 98.8 ± 3.9 480. 2 ± 4.3 * 98.5 ± 6.1 478.9 ± 10.5 * P aO 2 (mmHg)
110.4 ± 6.3 670.9 ± 13.5 * 111.3 ± 7.9 657.3 ± 41.4 * P ETCO 2 (mmHg) 40.6 ± 1.0 40.4 ± 1.0 40.3 ± 0.7 40.4 ± 0.7 P aCO 2 (mmHg)
35.4 ± 2.4 35.7 ± 3.3 34.9 ± 2.7 34.6 ± 2.9 O 2 Saturation (%) 98.8 ± 0.3 100 ± 0.0
11.6 ± 4.5 11.5 ± 3.5 11.6 ± 2.8 12. 13.9 ± 2.0 14.5 ± 1.9 14.5 ± 2.4 15.4 ± 2.3 BF (mL min −1 )
108.3 ± 27.5 102.0 ± 32.4 109.9 ± 32.0 111.5 ± 29.9 VC (mL min −1 mmHg −1 )
1 . 0 ± 0.3
20.5 ± 5.5 21.3 ± 6.9 19.7 ± 6.2 21.9 ± 6.6
Values are mean ± SD. * P < 0.05, 21% O 2 vs. 100%O 2 ; † P < 0.05, Saline vs. Ascorbic acid. BF, blood flow; CO, cardiac output; COF, cardiac output fractional distribution; D O 2 , delivery of oxygen; HR, heart rate; MAP, mean arterial pressure; P aCO 2 , arterial carbon dioxide arterial pressure; P aO 2 , arterial oxygen arterial pressure; P ETCO 2 , end tidal carbon dioxide arterial pressure; P ETO 2 , end tidal oxygen arterial pressure; VC, vascular conductance.
Transcerebral exchange (TCE) of AA, AA+DA, 8-isoprostane, TBARS and neuron-specific enolase (NES) were also calculated from both the NX and IH trials as follows:
Where AAA is arterial ascorbic acid, VAA is venous ascorbic acid, AAA+DA is arterial ascorbic acid plus dehydroascorbic acid, VAA+DA venous ascorbic acid plus dehydroascorbic acid, A8-isoprostane is arterial 8-isoprostane, V8-isoprostane is venous 8-isoprostane, ATBARS is arterial TBARS, VTBARS is venous TBARS, ANES arterial neuron-specific enolase, and VNES is venous neuron-specific enolase.
Statistics
The results are expressed as mean ± standard deviation (SD) and normal distribution was verified using the Shapiro-Wilk test. A repeated-measures two-way analysis of variance (ANOVA) was then conducted to detect significant main effects and time-condition interactions. Fisher's post hoc test (LSD) was conducted as a multiple comparison analysis. When parametric distribution was confirmed, differences between values obtained during isocapnic hyperoxia and normoxia trials ( ) with the infusion of saline or AA were calculated and compared in a two-tailed paired Student's t test. When the assumption of normality was not met, statistical inference was obtained using the Wilcoxon signed-rank test. Significance was assumed when P ࣘ 0.05. All analyses were performed using the Prism 7.0 for Windows (Graphpad Software, San Diego, CA, USA).
Results
Due to technical problems with the gas analyser, blood gas-derived parameters were quantified for only 9 out of 10 subjects. VABF: −6.3 ± 11.4 mL min −1 , P = 0.0007) when compared to VA, while only a tendency was observed between the relative changes ( ICABF: −17.2 ± 9.6 vs. VABF: −6.7 ± 9.4%, P = 0.067). In contrast, intravenous AA abolished not only the reduction in regional BF but also the absolute ( ICABF: +19.1 ± 31.38 vs. VABF: +1.7 ± 18.8 mL min −1 , P = 0.1534) and relative ( ICABF: +6.4 ± 11.2 vs. VABF: +4.6 ± 19.7%, P = 0.739) changes in vascular reactivity between the arteries. tCBF (Fig. 2) and VTVC (NX: 8.5 ± 1.7 vs. IH: 7.2 ± 1.6 mL min −1 mmHg −1 , P = 0.002) were reduced during IH, whereas intravenous AA infusion reversed these responses (VTVC NX: 8.1 ± 1.4 vs. IH: 8.2 ± 1.6 mL min −1 mmHg −1 , P = 0.752). IH also evoked reductions in molar tCBF and VTVC during the saline infusion, whereas these responses were blunted during the AA infusion (Table 2) . C aO 2 and C vO 2 increased in similar fashion when the subjects breathed 100% O 2 , and EF O 2 remained unchanged throughout the protocol. No variation was observed for AGlu, ALac, VGlu, VLac, EF Glu and EF Lac . Hyperoxia provoked a significant reduction in CD O 2 during the saline infusion. Although CD O 2 was smaller in the normoxic state during the AA infusion, it was increased when subjects breathed 100% O 2 (Fig. 2) . CD Glu , CD Lac and CMR O 2 were reduced in the hyperoxic state, whereas no changes were observed when AA was infused. CMR Glu was also reduced during IH and the saline infusion, while CMR Lac , OGI and OCI did not change throughout the protocol (Table 2) . Table 3 shows the arterial and jugular venous concentrations of AA and AA+DA as well as their TCEs throughout the protocol. AA and AA+DA arterial and venous concentrations increased during the AA infusion compared to the saline infusion in both the normoxia and hyperoxia trials. While AA TCE did not change throughout the protocol, AA+DA TCE was reduced during the hyperoxic trial and the AA infusion, indicating its absorption by the brain.
The 8-isoprostane analyses involved only nine subjects due to technical problems with arterial samples. Figure 3 indicates that hyperoxia evoked an increase in the 8-isoprostane arterial concentrations. In contrast, the arterial concentration of 8-isoprostane decreased when hyperoxia was induced during the AA infusion (NX: 84.6 ± 37.7 vs. IH: 57.2 ± 25.8 pg mL −1 , P = 0.002). The jugular venous concentration of 8-isoprostane only decreased in the hyperoxic trial during the AA infusion. The TCE of 8-isoprostante did not change under hyperoxaemic conditions. As highlighted in Table 4 , IH did not impact the arterial or venous TBARS or TBARS TCE. In contrast, TBARS TCE was reduced during IH with the AA infusion.
Nitrite analyses involved nine subjects, also due to technical problems with the arterial samples. Figure 4 indicates that the arterial and jugular venous concentrations of nitrites did not change during IH. On the other hand, TCE increased with IH during the saline infusion, indicating a lower brain release of nitrite. NSE analyses also involved only 9 out of 10 subjects. Table 5 indicates that the NSE arterial and jugular venous concentrations, as well as its TCE, did not change throughout the protocol.
Discussion
This investigation tested the hypothesis that IH affects human CBF and metabolic regulation through exaggerated ROS production and thus reduced NO bioavailability. Indeed, ICABF, tCBF, and CMR O 2 were reduced during IH with saline infusion. These responses were followed by an increase in 8-isoprostane arterial concentration and a reduction in NO end-product release (nitrite TCE), suggesting that changes in BF, especially in the anterior cerebral circulation, and metabolic regulation of the brain resulted from a rise in oxidative stress and a consequent decrease in NO bioavailability. In contrast, when AA was infused, the increase in antioxidant defences (as indicated by plasma concentrations of AA and AA+DA and its TCE) inhibited IH-induced changes in 8-isoprostane and nitrite TCE, demonstrating that AA prevented the rise in oxidative stress and the reduction in NO bioavailability. Consequently, IH-induced reductions in ICABF, tCBF and CMR O 2 were attenuated during AA infusion. Contrary to the experimental hypothesis, IH-induced increases in ROS production evoked neither a shift from brain oxidative to non-oxidative metabolism nor changes in NSE concentration. Thus, these findings 6 . 1 ± 0.8 6.2 ± 0.7 6.1 ± 1.0 6.1 ± 1.0 VGlu (mmol L −1 ) 5 . 2 ± 0.9 5.3 ± 0.9 5.3 ± 1.0 5.3 ± 0.9 EF Glu (%)
15.1 ± 5.9 14.2 ± 5.4 13.3 ± 4.8 13.6 ± 3.4 ALac (mmol L −1 )
1 . 8 ± 0.9 1.7 ± 0.9 1.8 ± 0.9 1.7 ± 0.8 VLac (mmol L −1 )
1 . 6 ± 0.5 1.5 ± 0.6 1.7 ± 0.6 1.7 ± 0.5 EF Lac (%) 2.4 ± 14.6 5.6 ± 28.2 −1. indicate the role of ROS in the regulation of tCBF and CMR O 2 during IH without evidence of disruption of the BBB or neural-parenchymal damage.
Methodological concerns and regional cerebrovascular reactivity
CBF regulation involves a large spectrum of regulatory mechanisms that, in concert, maintain nutrient and oxygen delivery to the brain . MAP, CO and P aCO 2 , for example, have been indicated as important CBF regulators Ogoh et al. 2017) . Throughout the experimental protocol, both MAP and CO remained unchanged, indicating that the observed tCBF responses were not affected by these variables. Similarly, P aCO 2 did not change between trials, demonstrating that the procedures adopted to maintain the isocapnic hyperoxic breathing pattern, such as the control of breathing rate and the use of a custom-made rebreathing system with simultaneous registration of P ETCO 2 , constituted an effective strategy to isolate the impact of an increase in P aO 2 on human CBF. Therefore, our findings confirmed that IH evoked arterial vasoconstriction and a resulting reduction in tCBF. Although J Physiol 597.3 controversial , IH-induced tCBF reduction was previously described (Floyd et al. 2003) with limited information on the local cerebrovascular responses or their contribution to BF reduction. We also quantified ICA and VA responses to IH. Supplementary oxygen evoked vasoconstriction in both conduit vessels, but only ICABF and VC were reduced during saline infusion. This indicates that the ICA is more responsive to IH than VA. In disagreement with our findings, Ainslie et al. (2014) did not report changes in both ICA and VABF during IH. Methodological aspects such as the inclusion of females in the sample of the study and the smaller IH-induced increase in P aO 2 emerge as likely candidates to explain the absence of changes in regional and tCBF. While females may be less susceptible to perturbations in the redox homeostasis due to the antioxidant properties of oestrogen and sex-associated differences in the activity of enzymes such as superoxide dismutase and NADPH oxidase (Miller et al. 2007; Kander et al. 2017) , the rate of ROS formation by the mitochondrial respiratory chain increases when the electron flow slows down or when the concentration of oxygen increases (Turrens, 2003) . Conversely, a decline in BF of all cerebral regions with the exception of parietal and left hemispheric frontal grey matter has been reported during IH (Kolbitsch et al. 2002) . These responses were also followed by an unchanged middle cerebral artery (MCA) velocity, an intracranial conduit vessel that feeds the fronto-parietal areas of the brain (Kolbitsch et al. 2002) . While there is no apparent explanation for the inconsistent findings, in our study, changes in ICABF were mainly driven by a reduction in its diameter without modifications in BV. As Kolbitsch et al (2002) did not quantify MCA diameter, we believe that the changes in BF during IH may have been underestimated, and at least in part, explain the disagreement between the studies. Regional cerebral heterogenic reactivity to changes in P aCO 2 (Sato et al. 2012) or oxygen desaturation (Willie et al. 2012) has also been reported, indicating a differential sensitivity of the posterior cerebral circulation (VA) to variations in arterial gases pressure. Similarly, we observed a differential response between ICA and VA to IH-induced increase in ROS production and decreased NO availability. Differential but inconsistent vasomotor tone responses to NO bioavailability (Perko et al. 2011; Vianna et al. 2018) may be involved in the heterogenic reactivity of the anterior and posterior cerebral circulation to IH-induced disturbance in redox homeostasis. Similarly, it has been interestingly postulated that the heterogeneous BF distribution in response to changes in arterial gases may constitute an evolutionary mechanism that protects phylogenetically 'old' regions of the brain, such as the cerebellum and the brainstem, with essential homeostatic roles (Sato et al. 2012) . Although it is attractive to speculate that it may also be the case in our findings, the mechanisms behind these local cerebrovascular responses still remain unclear and deserve further investigation.
ROS production and NO bioavailability
Hyperoxia disturbs redox homeostasis (Carpagnano et al. 2004; Brugniaux et al. 2018) , thereby reducing NO bioavailability and evoking vasoconstriction (Floyd et al. 2003; Farquhar et al. 2009; Caruana & Marshall, 2015) . We then hypothesized that IH-induced reduction in local and tCBF was a consequence of exaggerated ROS production. In rats, hyperbaric oxygen exposure reduced CBF and brain NO end-products via excessive ROS production (Zhilyaev et al. 2003) . In the present study, reductions in ICA parameters, tCBF, mtCBF, VTVC, mVTVC and CD O 2 , were followed by increases in 8-isoprostane arterial concentrations and nitrite TCE. This indicates that IH-induced reduction in CBF results from an increase in ROS production that, in turn, decreases NO bioavailability as shown by a reduction of nitrite release from the brain. Hyperoxia-induced NADPH oxidase activation and the excessive formation of superoxide anions (Dean et al. 2004 ) may be the pathway by which IH increases ROS production and decreases NO bioavailability. Based on that, evidence from animal models indicates that an increased brain antioxidant defence blunts hyperoxia-induced reductions in both CBF and brain NO end-products (Vucinovic et al. 2015) . In this study, intravenous AA infusion increased brain antioxidant defences, as shown by a reduced TCE and increased arterial/venous concentrations of AA and AA+DA, which crosses the BBB (Agus et al. 1997; Huang et al. 2001) . AA+DA TCE kinetics were followed by a reduction in jugular venous 8-isoprostane, a decrease in the release of TBARS from the brain (increased TCE) and no change in nitrite TCE. Therefore, the restoration of CD O 2 , CBF, and conductance confirms the role of ROS in IH-induced reduction in the human brain blood flow.
Metabolic regulation of the brain during IH
IH-induced reduction in CD O 2 and CBF was also related to a decrease in CMR O 2 . While there are certain discrepancies in the literature (Xu et al. 2012; Ainslie et al. 2014) , our findings corroborate the MRI-based evidence indicating a decrease in human brain oxidative metabolism under hyperoxic conditions (Xu et al. 2012) . Since arterial and venous oxygen content increased and no change was observed in the oxygen extraction fraction, the reduction in CMR O 2 was driven by reduced CBF. However, ROS-evoked inhibition of aerobic enzymatic activity (Bogaert et al. 1994 ) and suppression of the neural J Physiol 597.3 
ROS, BBB disruption and neural-parenchymal damage
In addition to the impact on CBF and metabolic regulation, accumulated ROS could disrupt the BBB (Pun et al. 2009 ) and cause neural-parenchymal damage (Terraneo et al. 2017) . Patients that have suffered cardiac arrest and received cardiopulmonary resuscitation, for example, present increased markers of neuronal-parenchymal injury (Kuisma et al. 2006 ) under hyperoxaemic conditions. Thus, we quantified arterial/venous and TCE kinetics of NES, the neuronal variant of the glycolytic enzyme that is exclusively located within neurons and neuroendocrine cells (Schmechel et al. 1978; Schoerkhuber et al. 1999) . Contrary to our hypothesis, NSE arterial/venous and TCE kinetics of NES did not change during IH, indicating that short-term exposure to supplementary oxygen did not evoke BBB disruption and neural-parenchymal damage in the young healthy human brain. Although our findings did not corroborate with previous evidence among patients with heart disease (Kuisma et al. 2006) , methodological aspects such as the study sample and the time in which hyperoxia was administered must be taken in account.
Limitations
Other methodological aspects should also be considered during the interpretation of these findings. A single trial of IH is not representative of the poikilocapnic hyperoxaemia administered as a medical therapy, limiting the extrapolation of our findings to clinical circumstances. Nonetheless, as poikilocapnic hyperoxaemia evokes hyperventilation-induced hypocapnia, which in turn provokes preferential decline in the perfusion of the anterior circulation of the brain (Sato et al. 2012) with repercussions on its metabolic profile , IH was intentionally chosen to investigate the isolated contribution of increased ROS production on local and total CBF, metabolic regulation, NO bioavailability, disruption of the BBB or neural-parenchymal damage. This study may also be limited by a relatively small sample size as most of the variables quantified inherently present high random variation. However, the final sample size had sufficient power to detect significant changes even in parameters such as 8-isoprostane and nitrite concentration that in turn have been characterized by a high between-subject variability. The fact that only men were investigated limits the extrapolation of these findings to women because females seem to be less susceptible to the perturbations in the redox homeostasis (Miller et al. 2007; Kander et al. 2017) . ROS accumulation was represented by the quantification of arterial and jugular vein plasma TBARS, a non-specific oxidative stress biomarker that has been criticized as being a non-specific marker of lipid peroxidation (Knight et al. 1988) . However, the quantification of plasma 8-isoprostane, a specific oxidative stress biomarker, and ascorbic acid arterial/jugular venous levels and TCE kinetics minimize the claimed lack of specificity of the lipid peroxidation marker.
Ultimately, a randomly defined order between saline and AA hyperoxia trials would avoid speculation of a likely time-based effect on the study results. However, we believe that this methodological concern does not invalidate our conclusions due to the following reasons. First, ROS formation increases when the electron flow slows down or when the concentration of oxygen is augmented (Turrens, 2003) , which is the case in our study as indicated by the P aO 2 data. Second, there is no available evidence indicating that saline infusion inhibits hyperoxia-induced ROS formation. Our data support this statement since we showed an increase in ROS production during hyperoxia with saline infusion.
It has also been shown that the infusion of the same concentration of AA used in this study successfully inhibited ROS production during hyperoxia. In our study, we show that this concentration of AA induced a large increase in plasma AA+DA, which increased the antioxidant defences and inhibited ROS production. In addition, if there were effects of time and saline or AA infusion, we would expect changes in AA trial baseline recordings. As indicated in the results, baseline recordings were similar between the trials for all dependent variables of the study. Finally, AA trials were always conducted after the saline trials since evidence indicates a controversy with regard to its half-life after venous infusion (Duconge et al. 2008 ). This in turn makes it difficult to define what is the best time interval between trials in the case of applying a random order for saline and AA bouts.
Conclusion
In summary, IH-induced decline in local and total cerebral blood flow and CMR O 2 was followed by an increase in oxidative stress and a reduction in NO end-product release. However, AA infusion-induced increase in plasma antioxidant defences inhibited ROS production and the resulting reduction in NO bioavailability, leading to unchanged blood flow and metabolic regulation of the human brain. Therefore, an exaggerated production of ROS plays a role in the regulation of regional and total cerebral blood flow and metabolism during isocapnic hyperoxia without evidence of disruption of the BBB or neural-parenchymal damage.
